Highlighting the Clinical Promise from Phase I/IIa Development of TUB-040 in Platinum Resistant Ovarian Cancer
- Explaining TUB-040 ADC design innovation across payload, conjugation and validated NaPi2b target
- Detailing proof-of-concept data and strong ORR from the emerging clinical profile of TUB-040
- Contrasting clinical performance to preclinical data to assess how well TUB-040 innovation has been translated into patient studies
- Highlighting the clinical development strategy and potential therapeutic impact of TUB-040 in PROC with an existing approved ADC therapy